Nephrology
News
Community genetic testing prompts behavior change in patients
“These two measurements – the change in blood pressure and increased kidney function tests – act as hallmarks for detecting beneficial lifestyle...
Case Reports
Pheochromocytoma: An Incidental Finding in an Asymptomatic Older Adult With Renal Oncocytoma
A high index of suspicion for pheochromocytoma is necessary during the workup of secondary hypertension as untreated pheochromocytoma may lead to...
Case Reports
Cisplatin-Induced Acute Kidney Injury and Renal Salt Wasting Syndrome
A treatment strategy that incorporates both water restrictions and sodium supplementation may be appropriate when differentiating between...
Conference Coverage
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
News
SGLT2 inhibitors for diabetes: No link to fractures in older adults
Analysis of Medicare data supports findings from younger adults that use of the drug class does not appear to raise fracture risk.
News
Fluoroquinolones linked to sudden death risk for those on hemodialysis
Most patients undergoing hemodialysis have a least one risk factor for drug-induced QT interval prolongation.
News
Women with recurrent UTIs express fear, frustration
“There is a need for physicians to modify management strategies ... and to devote more research efforts to improving nonantibiotic options for the...
News
FDA okays difelikefalin for dialysis-associated pruritus in patients with CKD
Pruritus in patients with chronic kidney disease on hemodialysis is common and has had no widely accepted go-to treatment.
Original Research
A Step Toward Health Equity for Veterans: Evidence Supports Removing Race From Kidney Function Calculations
The incorporation of a race coefficient in kidney estimation equations lacks biological plausibility and its use exacerbates kidney health...
Conference Coverage
‘Stunning’ twincretin beats semaglutide for A1c, weight reduction in T2D
Head-to-head pivotal trial results show weekly tirzepatide injections surpassed 1 mg semaglutide weekly for A1c reduction and weight loss.